Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10217302 | 0.87 | OPRL1 (0.36) | SMN1; SMN2MAPTOPRM1OPRL1OPRD1 | |
| SCHEMBL10119956 | 0.82 | OPRL1 (0.43) | SMN1; SMN2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL16980438 | 0.81 | OPRM1 (0.37) | OPRM1OPRL1OPRK1 | |
| SCHEMBL19630699 | 0.81 | OPRM1 (0.34) | OPRM1OPRL1OPRK1 | |
| SCHEMBL17834049 | 0.80 | OPRL1 (0.36) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL10217420 | 0.79 | — | — | |
| SCHEMBL18557138 | 0.79 | OPRM1 (0.36) | OPRM1OPRL1OPRK1 | |
| SCHEMBL20402865 | 0.79 | OPRM1 (0.36) | OPRM1OPRL1OPRK1 | |
| SCHEMBL15222420 | 0.79 | OPRM1 (0.36) | OPRM1OPRL1OPRK1 | |
| SCHEMBL10140532 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | SMN1; SMN2 2114/4885MAPT 1271/4885OPRM1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.